Headlines about Lumenis (NASDAQ:LMNS) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Lumenis earned a news impact score of 0.20 on Accern’s scale. Accern also gave headlines about the medical equipment provider an impact score of 44.8955897798361 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
WARNING: This news story was posted by BBNS and is the property of of BBNS. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://baseballnewssource.com/2018/03/22/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-lumenis-lmns-stock-price/1926538.html.
Lumenis Company Profile
Lumenis Ltd. (Lumenis) is a provider of energy-based, minimally invasive clinical solutions. The Company operates through three segments: surgical, ophthalmic and aesthetic. The Company offers energy-based solutions for medically necessary and elective procedures, primarily for the aging population. Its solutions include the holmium laser, the Lumenis Pulse 120H, used for urologic applications; the VersaPulse PowerSuite platform which uses holmium lasers for urologic applications; the M22 multi-energy, a multi-application platform for the treatment of various skin conditions, and the Selecta multi-modality platform for retinal, secondary cataract and glaucoma therapies.
Receive News & Ratings for Lumenis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumenis and related companies with MarketBeat.com's FREE daily email newsletter.